TransMedics Group (TMDX) Peer Comparison

$91.75

$-0.47 (-0.51%)

As on 27-Aug-2026 16:09EDT

Market cap

$3,286 Mln

Revenue (TTM)

$668 Mln

P/E Ratio

24.6

P/B Ratio

6.1

Div. Yield

0 %

Edit

	TransMedics Group (TMDX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	3,286	12,753	10,906	9,762	10,222
Revenue ($ Mln)	668	1,505	613	2,589	785
Net Profit ($ Mln)	151.70	160.59	-188.05	222.40	41.54
Net Margin (%)	22.69	10.67	-30.68	8.59	5.29
RoE (%)	30.61	10.86	-28.10	3.04	1.97
Price to Earnings	24.55	79.35	--	44.47	251.57
Price-To-Book	6.08	8.41	16.38	1.26	4.84

Income Statement ($ Mln)

	TransMedics Group (TMDX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	668.47	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	276.12	483.98	127.96	1,245.50	384.30
Gross Profit	362.81	942.44	393.22	1,343.60	347.62
Operating Expenses	310.74	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	81.61	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	72.55	203.83	-192.83	350.40	52.15
Provision for Tax	-79.15	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	151.70	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

	TransMedics Group (TMDX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	518.05	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	848.06	210.18	135.71	2,116.80	705.49
Current Liabilities	98.28	233.78	102.33	961.30	132.66
Total Liabilities	1,068.37	1,826.52	893.49	10,576.50	2,949.70

	TransMedics Group (TMDX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	813.27	630.60	404.74	7,231.50	1,749.63
Current Assets	651.12	1,344.12	515.78	3,020.50	1,200.55
Total Assets	1,068.37	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	867.72	212.71	102.84	1,203.70	690.94
Net Current Assets	552.84	1,110.35	413.45	2,059.20	1,067.90

	TransMedics Group (TMDX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	192.84	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-59.25	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	16.86	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

	TransMedics Group (TMDX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	22.52	11.76	-22.53	8.98	1.79
ROE (%)	30.61	10.86	-28.10	3.04	1.97
ROA (%)	12.09	7.95	-18.00	2.02	1.36
EBIT Margin (%)	10.05	13.63	-30.58	-5.99	9.87
Net Margin (%)	22.69	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	TransMedics Group (TMDX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	25.82	17.55	41.55	1.37	16.49
EBIT Growth (%)	-23.87	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	111.69	8.72	-102.66	-30.32	400.42
EPS Growth (%)	105.53	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	62.26	17.33	-12.65	2.19	2.16

	TransMedics Group (TMDX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	26.16	68.93	-34.59	--	189.42
Price / Book Value	10.52	8.58	9.90	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	33.40	53.25	-43.50	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

	TransMedics Group (TMDX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.95	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.05	0.01	0.00	0.06	0.01
Current Ratio	6.62	5.75	5.04	3.14	9.05
Quick Ratio	6.07	3.86	4.46	2.33	7.64
Interest Coverage	4.42	157.91	-38.31	8.18	3.36

	TransMedics Group (TMDX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	15.58	12.65	22.67	17.06	20.09
Asset Turnover	0.53	0.74	0.59	0.24	0.26
Receivable days	54.89	46.54	60.95	65.39	72.41
Inventory Days	71.82	331.92	193.84	221.09	146.53
Payable days	15.53	26.16	60.19	37.02	29.05
Cash Conversion Cycle	111.18	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.